Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE.
ANAPROX DS vs IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Diphenhydramine is an antihistamine that antagonizes histamine H1 receptors.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
1-2 tablets (200 mg ibuprofen/25 mg diphenhydramine HCl each) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Ibuprofen: 2-4 hours (immediate-release). Diphenhydramine: 8-12 hours (prolonged in hepatic impairment).
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Ibuprofen: Renal (90% as glucuronide conjugates, <10% unchanged). Diphenhydramine: Renal (primarily as metabolites, <10% unchanged). Both undergo hepatic metabolism with renal excretion of metabolites.
Category C
Category D/X
NSAID
NSAID